Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Lenvatinib (off Label)

ACC-LEN14

Eisai (investigator studies) · Phase 2 · Completed · Enrollment 26

NCT02860936

ArmReported safety
Lenvatinib 24 mggrade 3 or higher treatment-related adverse events: 50%, primary analysis

A count stays a count. This page does not turn a count into a percent.